With an FDA-approved, non-opioid drug in commercial production, a revolutionary chemotherapy alternative in pre-clinical trials, and a potential COVID therapeutic in the works, Q BioMed (OTC: QBIO) is poised for major growth in the near-term.
Q BioMed’s recent announcement of its contract manufacturing facility’s FDA approval and subsequent commercial launch of Strontium89 makes it that rare micro-cap issuer with imminent revenue. The company has a number of potential new drugs in its pipeline, but its commercial ready assets, in particular, are what sets this company apart from its peers.
Q BioMed (OTCQB: QBIO) treats its first commercial patient with a non-opioid alternative for the alleviation of cancer-related bone pain
The widespread push to reduce the use of opioids means that clinicians are actively seeking effective alternatives. Opioid addiction is at crisis levels.
But addiction isn’t the only problem with opioids. For those with the most severe pain, there are few alternatives. Yet the side effects of opioids can be so bad that many patients prefer the pain.
Brain fog, nausea, vomiting, abdominal distention, and constipation can be excruciating for opioid users. What’s worse, prolonged use can lead to tolerance, which means the drug is no longer able to mask the pain.
For the hundreds of thousands who suffer from cancer that has spread to the bone, Q BioMed’s (OTCQB: QBIO) Strontium Chloride offers an alternative to the horrors of opioids.
Strontium Chloride is non-addictive, works in 80% of patients, and continues working for up to six months with a single dose
Strontium Chloride is specifically designed to target pain caused by cancer that has spread to the bone, which is a common occurrence in prostate, breast, and lung cancers, among others.
The active ingredient in Strontium 89 Chloride is a radioactive isotope of the chemical element strontium. When injected into the body strontium acts like calcium, being taken into the bone at the sites of growing tumors and lesions.
It then delivers targeted radiation directly to the tumor sites, relieving pain
Q BioMed (OTCQB: QBIO) owns the generic version of the drug and also recently bought the brand name of Strontium Chloride, Metatron, from GE Healthcare, where it surprisingly never got the marketing resources necessary to grow sales, even though it’s development was hailed by the pharmaceutical and biotechnology industries as a “major advance” in pain control.
Strontium Chloride is FDA-approved, and Metatron, the brand, is approved for sale in 22 countries. It is reimbursable by Medicare and most health plans. On November 20, 2019, the FDA approved Q BioMed’s U.S. based contract manufacturing facility and the Company expects a roll-out of Strontium 89 in early 2020.
The next step is to seek approval for an expanded indication, beyond pain therapy, as a cancer treatment, giving Q BioMed (OTCQB: QBIO) entry into the cancer therapeutic market.
Importantly, there is evidence to support this strategy. For example, a Phase II clinical trial published in the medical journal The Lancet showed that cancer patients lived nine months longer when given Strontium Chloride as a combination therapy, significantly longer than the leading prostate cancer drug.
The Company plans to undertake a Phase IV trial, sometimes called a post-marketing study, to confirm those results.
A positive result would allow Q BioMed (OTCQB: QBIO) to market this drug for both therapeutic and pain indications.
Pain associated with bone cancer is an underserved market
It is estimated that over 10,000,000 people are living with painful skeletal metastatic cancer today. In addition, an expected 20-30% of breast and prostate cancer diagnoses will develop metastatic disease, as well as most other primary cancers.
Q BioMed intends to pursue label expansion to include therapy for bone metastasis from several primary cancers, possibly in combination with other therapies, such as external beam radiation therapy, of which there are 500,000 treatments a year in the US for bone pain.
Strontium Chloride is just one of the drugs in Q BioMed’s (OTCQB: QBIO) pipeline ready for commercialization.
That isn’t the only news driving heightened interest in Q BioMed.
In a recent announcement, Q BioMed (OTCQB: QBIO) declared its intention to enter into a financial restructuring of approximately $7.8 Million. This restructuring of $3.8 Million debt and $4 Million in new capital creates substantial positive shareholder equity, ultimately fulfilling the requirements for a Nasdaq listing anticipated in the not-too-distant future.
This influx of new capital offers Q BioMed enough runway to bring its FDA-approved, non-opioid, Strontium89 Chloride drug into full commercialization, as well as advance other key pipeline assets.
A robust pipeline of developmental drugs
Q BioMed (OTCQB: QBIO) follows an unconventional business model in the micro-cap pharma sector. The Company conducts its own research to identify innovative technologies that have been under-served, undervalued, or ignored, but which management believes have inherent potential. Although it does not invent those technologies, it attempts to create greater value through the use of its human capital and economic investments.
By carefully building a portfolio of assets in the pre-clinical stage, Phase I trials, one commercial ready asset, and one that has just found an entrance to the commercial market, the Company hopes to build value for its patients and shareholders for years to come.
Q BioMed (OTCQB: QBIO) partner, Mannin Research Inc., set to fast-track potential Coronavirus therapy
Q BioMed has been the focus of a lot of investor attention in recent weeks following an aptly timed announcement.
The February press release pointed to a project in the works since last September when the German state of Saxony awarded Mannin a $7.7 million grant to advance its novel therapeutics.
Mannin has since been fast at work developing a new class of therapeutics that lowers the severity of infection for vascular pathologies, including coronaviruses like COVID-19 and SARS, as well as the common flu, which claims more than 600,000 lives globally every year.
By reducing endothelial dysfunction and loss of endothelial barrier integrity, the companies hope to halt the development of acute lung injury following severe viral or bacterial infections.
Q BioMed CEO Denis Corin states,
“We are working closely with our technology research partner Mannin to develop a potential adjunct treatment for various infectious diseases like the coronavirus. These types of outbreaks are not uncommon. H1N1, SARS, Ebola, pneumonia, influenza, and others all can cause vascular leakage and respiratory distress in patients, which can be fatal in the most severe cases.”
New hope for those with liver cancer, glaucoma, and more
Some of Q BioMed (OTCQB: QBIO) products are preclinical stage therapies for liver cancer, glaucoma, acute kidney injury, pulmonary artery hypertension, and infectious diseases.
The Company is partnering with the Oklahoma Medical Research Foundation, licensing its liver cancer drug candidate, a new type of naturally-derived chemotherapy.
Q BioMed (OTCQB: QBIO) recently announced an important breakthrough in this program. Together with its collaborators, they have successfully synthesized the naturally occurring plant molecule that has shown the potential to be 10 times more potent than the current first-line liver cancer drug. Data supporting this conclusion was published in the November 2016 issue of Scientific Reports, a Nature journal.
The potential therapeutic shows remarkable efficacy in HepG2 Cell Lines, the most common form of liver cancer. Q BioMed (OTCQB: QBIO) anticipates filing an Orphan Drug Application followed by an Investigational New Drug Application for a Clinical Program with the expectation of commencement in 2020.
The compound was isolated and characterized from the leaves of Solanum Nigrum Linn, a plant widely used in traditional medicines. Uttroside B as it is known, drastically shrunk tumors in mice bearing human liver cancer xenografts. In addition, in pre-clinical experiments, Uttroside B induced cytotoxicity in all liver cancer cell lines, and researchers were also able to confirm its biological safety, both by in vitro and in vivo studies.
This means that this potential drug may ultimately be a treatment for liver cancers. The first hurdle of making a synthetic version of it has been achieved. Q BioMed (OTCQB: QBIO) will now advance the most promising candidates into preclinical testing and validation in 2020 in anticipation of an orphan drug application and an IND clinical program.
Chemotherapeutic options for liver cancer are limited, and the prognosis of liver cancer patients remains very challenging.
According to the Centers for Disease Control and Prevention, it is the second most common cause of cancer deaths worldwide, claiming approximately 750,000 lives each year.
In the US, the American Cancer Society estimates that 42,000 people will be diagnosed with liver cancer in 2019 and that 32,000 will die from the disease this year.
Liver cancer incidence has more than tripled since 1980 and deaths in the US have increased 56% since 2003.
Q BioMed (OTCQB: QBIO) also has a partnership with Mannin Research Inc, with an option to acquire any or all of its pipeline of drugs. Mannin has made some impressive announcements about its glaucoma program recently that set it apart from its peers, and we expect to see this pipeline develop into other therapeutic areas.
All of these drugs are targeted in large markets with millions of potential patients.
Now is a good time to follow the company
Q BioMed (OTCQB: QBIO) announced FDA approval of their contract manufacturing facility in November 2019. The company expects to start producing the drug and have it on the market generating revenue early in 2020.
Ask your broker about Q BioMed (OTCQB: QBIO) and always remember to do your own due diligence.
This report is for information purposes only and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions, and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor’s reliance on the use of this material. Financials Trend has been compensated 20k for coverage of this stock by Think Ink Marketing this month. Financials Trend and its affiliates or officers currently hold no shares of this stock. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend’s websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words “may”, “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend,” ” project,” and similar expressions and variations thereof are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.